A study testing whether a new weekly shot from University of Southern California, tirzepatide, can help people drink less.

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

• Meeting past-year DSM-5 criteria for AUD with at least moderate severity (>= 4 symptoms)
• Average daily consumption of >=40g (women) / >= 60 g (men) per day in the 28 days prior to baseline
• Body mass index >= 27kg/m2
• Willingness to attend weekly medication visits and complete all study procedures
• Ability to read and communicate in English

Key exclusion criteria

• Meeting past-year DSM-5 criteria for another substance use disorder (except tobacco use disorder or mild cannabis use disorder)
• Recent (past 30 day) self-report of illicit drug use (excluding cannabis) or non-prescribed opioids; or positive urine screen for illicit drugs. A positive screen for opioids will be allowed if the participant is prescribed an opioid replacement therapy medication and can provide documentation.
• History of significant alcohol withdrawal, as indicated by history of seizure, delirium tremens; history of hospitalization for withdrawal-related symptoms; a CIWA score >9 at assessment; or a baseline score 4+ on the Prediction of Alcohol Withdrawal Severity (PAWS) scale.
• Recent (past 3 months) engagement in behavioral or pharmacological alcohol use treatment or currently mandated to receive treatment
• History of chronic or acute pancreatitis